Loading...
News Releases2022-03-07T09:43:57-05:00
December 17, 2020

Advanced Proteome Therapeutics Announces Dr. Benjamin Krantz to Join Company as CEO

December 17th, 2020|

Advanced Proteome Therapeutics Corporation (“APC” or the “Company’) (TSXV: APC) (FSE: 0E8), is pleased to announce that Dr. Benjamin Krantz will be joining the Company’s US subsidiary Advanced Proteome Therapeutics Inc. (“APTI”) as CEO following the completion of his oncology fellowship at NYU Langone Health on July 1st, 2021. Bill Dickie will continue his role as interim CEO of APTI until then and remain a member of the board of directors after.

December 3, 2020

Advanced Proteome Therapeutics Announces Options Grants and Cancelations

December 3rd, 2020|

Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), announces that it has granted 1,575,000 incentive stock options to directors, officers, and consultants. The incentive stock options have an exercise price of $0.11 per share, are valid for a 2-year period from the date of grant, and are subject to regulatory approval.

November 16, 2020

Advanced Proteome Therapeutics Provides Update on Projects

November 16th, 2020|

Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), reports that its US subsidiary, Advanced Proteome Therapeutics Inc. (“APTI”), has provided the following update on projects in progress.

September 29, 2020

Advanced Proteome Therapeutics Provides Update

September 29th, 2020|

Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), is pleased to announce that it’s US subsidiary, Advanced Proteome Therapeutics Inc. (“APTI”), is rapidly advancing two projects with the near-term potential to add significant shareholder value.

July 9, 2020

Advanced Proteome Therapeutics Files Provisional LP for Compounds Targeting SARS-COV-2

July 9th, 2020|

Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), is pleased to announce that it’s US subsidiary, Advanced Proteome Therapeutics Inc. (“APTI”), has filed for patent protection on a family of therapeutic candidates against SARS-CoV-2, the virus which causes COVID-19 and has initiated a project to rapidly manufacture test quantities of these drugs.

June 8, 2020

Advanced Proteome Therapeutics Announces Collaboration on Antibody-radioisotope Conjugates

June 8th, 2020|

Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), is pleased to announce that it’s US subsidiary, Advanced Proteome Therapeutics Inc. (“APTI”), has initiated a collaboration with Dr. Brian Zeglis at the City University of New York to test APTI’s site specific conjugation technology in the rapidly growing field of radioimmunoconjugates (RICs). APTI will prepare RICs using its proprietary conjugation technology with antibodies targeting the HER2 receptor. The HER2 receptor is expressed on many malignancies with approved targeted therapeutics for breast and gastric cancer. Under the collaboration, RICs produced with APTI conjugation technology will be chemically characterized, imaged by PET and in vivo bio-distribution evaluated.

May 28, 2020

Advanced Proteome Therapeutics Announces First Results of Pilot Project

May 28th, 2020|

Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), is pleased to announce that it’s US subsidiary, Advanced Proteome Therapeutics Inc. (“APTI”), has received first results as part of its collaborative pilot project with a promising Boston based biotechnology company (“Biotech”), as announced on February 10, 2020. The pilot project is testing APTI’s site specific conjugation technology with Biotech’s proprietary antibody against a high-value target.

May 26, 2020

Advanced Proteome Therapeutics Announces Options Grant

May 26th, 2020|

Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), announces that it has granted 150,000 incentive stock options to a consultant to the company as per an agreement dated February 26, 2020, in accordance with the provisions of its 10% rolling stock option plan. The incentive stock options have an exercise price of $0.09 per share, are valid for a 2-year period from the date of grant, and are subject to regulatory approval.

Go to Top